Novartis Outlook Indicates No Patent Cliff Beyond 2025 -- Market Talk

Dow Jones
2025/02/04

0811 GMT - Novartis is set to overcome a wave of patent expirations during 2025, Deutsche Bank analyst Emmanuel Papadakis says in a note. The Swiss pharma giant surprised with its margin performance in the last quarter and its 2025 outlook that came ahead of analysts expectations, he says. While some of the 4Q revenue beat was attributed to rebates, Novartis appears well-positioned to continue exceeding market expectations, the analyst says. Deutsche Bank lifts back the stock rating to buy from hold, which had been previously nudge down due to patent expiry worries. (helena.smolak@wsj.com)

 

(END) Dow Jones Newswires

February 04, 2025 03:12 ET (08:12 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

应版权方要求,你需要登录查看该内容

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10